Migraine induction with calcitonin gene-related peptide in patients from erenumab trials

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

Thirteen migraine patients, previously enrolled in erenumab anti-CGRP receptor monoclonal antibody trials, received CGRP in a double-blind, placebo-controlled, randomized cross-over design to investigate their susceptibility to migraine induction.

Why It Was Studied

Retrospectively registered at clinicaltrials.gov with identifier: NCT03481400 .

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

The patients were stratified into groups of high responders and poor responders.

All interviews and experiments were performed in laboratories at the Danish Headache Center, Copenhagen, Denmark.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received CGRP (Calcitonin Gene-Related Peptide).

Some participants received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.

Each person switched between CGRP (Calcitonin Gene-Related Peptide) and the comparison at some point, usually with a gap in between.

Primary outcomes were incidence of migraine-like attacks and area under the curve of headache intensity after infusion of CGRP and placebo.

What Was Measured

PubMed files the paper under topics including Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Denmark and Migraine Disorders.

The authors tagged it with the keywords Biomarker, CGRP, Headache and Monoclonal antibody.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (The journal of headache and pain), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.